12/18
11:49 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.
12/18
08:14 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]
12/18
08:00 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
11/29
04:25 pm
rnaz
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
High
Report
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
11/27
07:09 am
rnaz
TransCode Therapeutics, Inc. Announces $8 Million Private Placement [Yahoo! Finance]
High
Report
TransCode Therapeutics, Inc. Announces $8 Million Private Placement [Yahoo! Finance]
11/27
07:00 am
rnaz
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
Medium
Report
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
11/26
07:05 am
rnaz
Transcode Therapeutics announces 1-for-33 reverse stock split [Yahoo! Finance]
High
Report
Transcode Therapeutics announces 1-for-33 reverse stock split [Yahoo! Finance]
11/25
07:00 am
rnaz
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
High
Report
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
11/15
08:03 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
11/12
07:00 am
rnaz
TransCode Therapeutics Open Letter to Shareholders
Medium
Report
TransCode Therapeutics Open Letter to Shareholders
11/5
07:00 am
rnaz
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
High
Report
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
10/24
08:08 am
rnaz
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
10/23
07:00 am
rnaz
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
High
Report
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
10/10
07:00 am
rnaz
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
High
Report
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology